Sp17 antibody, Blocking Peptides conjugate

Contents: Sp17 (C17) Blocking Peptide
Catalog Number: 66-P762
Formulation: Each vial contains 100 μg of peptide in 0.5 ml PBS with 0.1% NaN₃ and 100 μg BSA.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.

Product Options

Price

Cat. No.

Size

To view relevant pricing,
please select your country
and resume browsing.

66-P762-81

50 ug

Available Formats of This Product
Cat. No.	Format	Excite (nm)	Emit (nm)	Reported Applications
66-P762	Blocking Peptides for anti-human Sp17 polyclonal	N/A	N/A	WB

Custom Product Requests
Need a custom product? Download the Custom Product Request Form and submit completed form to customs@ebioscience.com.

Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq.

Description

This is a peptide mapping to the carboxy terminal domain of human Sp17. The highly immunogenic cancer-testis antigen Sp17 was originally thought to be expressed exclusively in the testis with the primary function of binding the extra cellular matrix of the oocyte (1,2). Upon further investigation Sp17 was found to be expressed by tumor cells with multiple myeloma in up to 30% of the cases studied (3,4). Sp17 has three functional domains, N-terminal, central, and C-terminal domains. The N-terminal domain contains an A-kinase anchoring protein binding motif. The central domain is necessary for heparin binding and the C-terminal domain contains a calmodulin-binding domain (1&2).

Applications Reported

For research use only, not for diagnostic or therapeutic use. This blocking peptide has been reported for use in competition studies.

References

1. Wen Y, Richardson RT, Widgren EE, O?Rand MG. 2001. Characterization of Sp17: a ubiquitous three domain protein that binds heparin. Biochem J. 357(Pt1):25-31.
2. Frayne J, Hall L. 2002. A re-evaluation of sperm protein 17 (Sp17) indicates a regulatory role in an A-kinase anchoring protein complex, rather than a unique role in sperm pellucida binding. Reproduction 124(6):767-774.
3. Chiriva-Internati M, Wang Z, Salati E, Wroblewski D, Lim SH. 2002. Succuessful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantion for Sp17-positive multiple myeloma. Scand J Immunology 56(4):429-433.
4. Chiriva-Internati M, Wang Z, Xue Y, Bumm K, Hahn AB, Lim SH. 2001. Sperm protein (Sp17) in multiple myeloma: opportunity for myeloma-specific donor T cell infusion to enhance graft-versus-myeloma effect without increasing graft-versus-host disease risk. Eur J Immunology 31(8):2277-2283.

Related Products

Cat. 14-6762 Purified anti-human Sp17 polyclonal (clone Polyclonal)